Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1122 | 1051 | 1122 | 883 | 1554 | 2544 |
Fund Return | 12.19% | 5.14% | 12.19% | -4.06% | 9.22% | 9.79% |
Place in category | 320 | 177 | 320 | 413 | 212 | 207 |
% in Category | 64 | 32 | 64 | 87 | 50 | 56 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Artisan International Value Instl | 21.79B | 6.64 | 6.91 | 7.76 | ||
Artisan International Value Advisor | 10.48B | 6.56 | 6.81 | - | ||
Artisan Mid Cap Advisor | 4.57B | 12.10 | -4.14 | - | ||
Artisan Mid Cap Investor | 4.57B | 11.97 | -4.28 | 9.53 | ||
Artisan International Small Cap Ins | 3.3B | -0.24 | -5.37 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Principal MidCap Institutional | 14.79B | 19.98 | 5.08 | 12.38 | ||
T. Rowe Price Mid-Cap Growth I | 13.14B | 9.54 | 0.73 | - | ||
Vanguard Mid-Cap Growth Index Admir | 12.51B | 16.41 | 0.66 | 10.40 | ||
T. Rowe Price Mid-Cap Growth | 12.25B | 9.40 | 0.60 | 10.24 | ||
T. Rowe Price New Horizons I | 10.02B | 3.99 | -7.28 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
argenx ADR | US04016X1019 | 4.64 | 653.43 | +2.12% | |
Tyler Technologies | US9022521051 | 3.76 | 588.78 | +0.47% | |
Ascendis Pharma AS | US04351P1012 | 3.56 | 127.62 | +1.43% | |
Spotify Tech | LU1778762911 | 3.55 | 499.58 | +1.22% | |
West Pharmaceutical Services | US9553061055 | 3.32 | 342.89 | -1.43% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Strong Buy |
Technical Indicators | Strong Buy | Strong Sell | BUY |
Summary | Strong Buy | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review